These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1637072)

  • 1. Antioxidative therapeutic strategies for Parkinson's disease.
    Shoulson I
    Ann N Y Acad Sci; 1992 May; 648():37-41. PubMed ID: 1637072
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention of progression of Parkinson's disease with antioxidative therapy.
    Grimes JD; Hassan MN; Thakar JH
    Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(2-3):165-72. PubMed ID: 3133719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutic strategies in Parkinson's disease].
    Shoulson I
    Arch Neurobiol (Madr); 1991; 54(6):277-81. PubMed ID: 1687429
    [No Abstract]   [Full Text] [Related]  

  • 4. Alpha tocopherol in CSF of subjects taking high-dose vitamin E in the DATATOP study. Parkinson Study Group.
    Vatassery GT; Fahn S; Kuskowski MA
    Neurology; 1998 Jun; 50(6):1900-2. PubMed ID: 9633757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Free-radical toxicity and antioxidant medications in Parkinson's disease.
    Ciccone CD
    Phys Ther; 1998 Mar; 78(3):313-9. PubMed ID: 9520976
    [No Abstract]   [Full Text] [Related]  

  • 6. Neuroprotective clinical strategies for Parkinson's disease.
    Shoulson I
    Ann Neurol; 1992; 32 Suppl():S143-5. PubMed ID: 1510374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease. The Parkinson Study Group.
    Shoulson I
    Eur Neurol; 1992; 32 Suppl 1():46-53. PubMed ID: 1425820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trials of neuroprotection in Parkinson's disease: long-term selegiline and alpha-tocopherol treatment.
    LeWitt PA
    J Neural Transm Suppl; 1994; 43():171-81. PubMed ID: 7884399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug trial for Parkinson's.
    Lewin R
    Science; 1987 Jun; 236(4807):1420. PubMed ID: 3109033
    [No Abstract]   [Full Text] [Related]  

  • 10. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism.
    Shoulson I
    Ann Neurol; 1998 Sep; 44(3 Suppl 1):S160-6. PubMed ID: 9749589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Free radicals in Alzheimer's dementia: currently available therapeutic strategies.
    Rösler M; Retz W; Thome J; Riederer P
    J Neural Transm Suppl; 1998; 54():211-9. PubMed ID: 9850930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group.
    Ann Neurol; 1998 Mar; 43(3):318-25. PubMed ID: 9506548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts.
    Marras C; Lang AE; Eberly SW; Oakes D; Fahn S; Schwid SR; Hyson C; Shoulson I;
    Mov Disord; 2009 Dec; 24(16):2370-8. PubMed ID: 19908310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of Parkinson's disease: are we at the end of the road?
    Nag D
    J Assoc Physicians India; 1992 Jun; 40(6):361-3. PubMed ID: 1360470
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group.
    Ann Neurol; 1996 Jan; 39(1):29-36. PubMed ID: 8572663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms?
    Olanow CW; Calne D
    Neurology; 1992 Apr; 42(4 Suppl 4):13-26; discussion 41-8. PubMed ID: 1584429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group.
    Ann Neurol; 1996 Jan; 39(1):37-45. PubMed ID: 8572664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Selegiline in Parkinson's disease; symptomatic or causal effect?].
    Wolters EC; Kuiper MA; Horstink MW
    Ned Tijdschr Geneeskd; 1992 Aug; 136(32):1544-7. PubMed ID: 1528279
    [No Abstract]   [Full Text] [Related]  

  • 19. [Current therapeutic approach in Parkinson disease].
    Przedborski S; Levivier M
    Rev Med Brux; 1992 Dec; 13(10):360-6. PubMed ID: 1480887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical neuromythology IX. Pyramid sale in the bucket shop: DATATOP bottoms out.
    Landau WM
    Neurology; 1990 Sep; 40(9):1337-9. PubMed ID: 2118239
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.